Search research articles
Contact Us
Filters
Showing results (31-40 of 63) with videos related to
Page
of 7
Sort By:
Current Medical Research and Opinion
|
May 27, 2017
A randomized, double-blind, non-inferiority trial evaluating the efficacy and safety of omarigliptin, a once-weekly DPP-4 inhibitor, or glimepiride in patients with type 2 diabetes inadequately controlled on metformin monotherapy
Yehuda Handelsman, Brett Lauring, Ira Gantz, et al.
Diabetes, Obesity & Metabolism
|
January 18, 2017
Randomized clinical trial comparing the efficacy and safety of treatment with the once-weekly dipeptidyl peptidase-4 (DPP-4) inhibitor omarigliptin or the once-daily DPP-4 inhibitor sitagliptin in patients with type 2 diabetes inadequately controlled on metformin monotherapy
Ronald Goldenberg, Ira Gantz, Paula J Andryuk, et al.
Journal of Diabetes
|
December 2, 2015
A randomized clinical trial evaluating the safety and efficacy of sitagliptin added to the combination of sulfonylurea and metformin in patients with type 2 diabetes mellitus and inadequate glycemic control
Robert G Moses, Elizabeth Round, Yue Shentu, et al.
BMC Endocrine Disorders
|
November 8, 2017
A randomized, placebo-controlled clinical trial evaluating the safety and efficacy of the once-weekly DPP-4 inhibitor omarigliptin in patients with type 2 diabetes mellitus inadequately controlled by glimepiride and metformin
Seung-Hwan Lee, Ira Gantz, Elizabeth Round, et al.
Diabetes, Obesity & Metabolism
|
January 29, 2021
A randomized, placebo-controlled study to evaluate the efficacy and safety of adding omarigliptin to insulin therapy in Japanese patients with type 2 diabetes and inadequate glycaemic control
Takashi Kadowaki, Yutaka Seino, Kohei Kaku, et al.
Clinical Therapeutics
|
September 20, 2017
Use of Prohibited Medication, a Potentially Overlooked Confounder in Clinical Trials: Omarigliptin (Once-weekly DPP-4 Inhibitor) Monotherapy Trial in 18- to 45-year-olds
Ira Gantz, Liubov Sokolova, Lokesh Jain, et al.
The Journal of Clinical Endocrinology and Metabolism
|
January 26, 2023
Ertugliflozin Delays Insulin Initiation and Reduces Insulin Dose Requirements in Patients With Type 2 Diabetes: Analyses From VERTIS CV
Samuel Dagogo-Jack, Robert Frederich, Jie Liu, et al.
Biochemistry
|
August 24, 2005
Interactions of human melanocortin 4 receptor with nonpeptide and peptide agonists
Irina D Pogozheva, Biao-Xin Chai, Andrei L Lomize, et al.
Diabetes, Obesity & Metabolism
|
March 10, 2022
Cardiorenal outcomes with ertugliflozin assessed according to baseline glucose-lowering agent: An analysis from VERTIS CV
Samuel Dagogo-Jack, Christopher P Cannon, David Z I Cherney, et al.
American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation
|
April 23, 2026
Association of Ertugliflozin on Kidney Outcomes in People After and Without an Interval Cardiovascular Event: Observations From the VERTIS CV Trial
Ayodele Odutayo, Francesco Cosentino, Richard E Pratley, et al.
Page
of 7
Search research articles
Search
Showing results (31-40 of 63) with videos related to
Sort By:
Page
of 7
Current Medical Research and Opinion
|
May 27, 2017
A randomized, double-blind, non-inferiority trial evaluating the efficacy and safety of omarigliptin, a once-weekly DPP-4 inhibitor, or glimepiride in patients with type 2 diabetes inadequately controlled on metformin monotherapy
Yehuda Handelsman, Brett Lauring, Ira Gantz, et al.
Diabetes, Obesity & Metabolism
|
January 18, 2017
Randomized clinical trial comparing the efficacy and safety of treatment with the once-weekly dipeptidyl peptidase-4 (DPP-4) inhibitor omarigliptin or the once-daily DPP-4 inhibitor sitagliptin in patients with type 2 diabetes inadequately controlled on metformin monotherapy
Ronald Goldenberg, Ira Gantz, Paula J Andryuk, et al.
Journal of Diabetes
|
December 2, 2015
A randomized clinical trial evaluating the safety and efficacy of sitagliptin added to the combination of sulfonylurea and metformin in patients with type 2 diabetes mellitus and inadequate glycemic control
Robert G Moses, Elizabeth Round, Yue Shentu, et al.
BMC Endocrine Disorders
|
November 8, 2017
A randomized, placebo-controlled clinical trial evaluating the safety and efficacy of the once-weekly DPP-4 inhibitor omarigliptin in patients with type 2 diabetes mellitus inadequately controlled by glimepiride and metformin
Seung-Hwan Lee, Ira Gantz, Elizabeth Round, et al.
Diabetes, Obesity & Metabolism
|
January 29, 2021
A randomized, placebo-controlled study to evaluate the efficacy and safety of adding omarigliptin to insulin therapy in Japanese patients with type 2 diabetes and inadequate glycaemic control
Takashi Kadowaki, Yutaka Seino, Kohei Kaku, et al.
Clinical Therapeutics
|
September 20, 2017
Use of Prohibited Medication, a Potentially Overlooked Confounder in Clinical Trials: Omarigliptin (Once-weekly DPP-4 Inhibitor) Monotherapy Trial in 18- to 45-year-olds
Ira Gantz, Liubov Sokolova, Lokesh Jain, et al.
The Journal of Clinical Endocrinology and Metabolism
|
January 26, 2023
Ertugliflozin Delays Insulin Initiation and Reduces Insulin Dose Requirements in Patients With Type 2 Diabetes: Analyses From VERTIS CV
Samuel Dagogo-Jack, Robert Frederich, Jie Liu, et al.
Biochemistry
|
August 24, 2005
Interactions of human melanocortin 4 receptor with nonpeptide and peptide agonists
Irina D Pogozheva, Biao-Xin Chai, Andrei L Lomize, et al.
Diabetes, Obesity & Metabolism
|
March 10, 2022
Cardiorenal outcomes with ertugliflozin assessed according to baseline glucose-lowering agent: An analysis from VERTIS CV
Samuel Dagogo-Jack, Christopher P Cannon, David Z I Cherney, et al.
American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation
|
April 23, 2026
Association of Ertugliflozin on Kidney Outcomes in People After and Without an Interval Cardiovascular Event: Observations From the VERTIS CV Trial
Ayodele Odutayo, Francesco Cosentino, Richard E Pratley, et al.
Page
of 7